BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) said members of its management team will present and hold one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in January, placing the clinical-stage biotech in front of a global audience of healthcare investors.
The presentation is scheduled for Wednesday, January 14, 2026, and will be accompanied by individual meetings throughout the four-day conference in San Francisco. Participation in the JPMorgan gathering is often viewed as a key visibility moment for emerging biotechnology companies seeking to highlight clinical progress and strategic direction.
Larimar is focused on developing treatments for complex rare diseases, with its lead drug candidate, nomlabofusp, under development for Friedreich’s ataxia, a rare, inherited neurodegenerative disorder with limited treatment options. The company is also advancing an intracellular delivery platform designed to enable fusion proteins that target other rare diseases driven by deficiencies in critical intracellular compounds.
Investor interest in rare disease drug development has remained strong, driven by high unmet medical need, regulatory incentives, and the potential for differentiated therapies. For Larimar, the JPMorgan conference offers a high-profile forum to outline its development plans and clinical roadmap as it works to advance its pipeline.
A replay of the company’s presentation will be available for 30 days on Larimar’s website following the event.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.